Involvement of interleukin 6 in SARS-CoV-2 infection : siltuximab as a therapeutic option against COVID-19
© European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ..
The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strategy for treating the disease. Siltuximab is a monoclonal antibody indicated in Castleman's disease that could be administered in a single dose of 11 mg/kg in severe forms of COVID-19 that have increased interleukin 6.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
European journal of hospital pharmacy : science and practice - 27(2020), 5 vom: 04. Sept., Seite 297-298 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Palanques-Pastor, Tomás [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.09.2020 Date Revised 18.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/ejhpharm-2020-002322 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310788889 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310788889 | ||
| 003 | DE-627 | ||
| 005 | 20231225140840.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/ejhpharm-2020-002322 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM310788889 | ||
| 035 | |a (NLM)32499314 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Palanques-Pastor, Tomás |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Involvement of interleukin 6 in SARS-CoV-2 infection |b siltuximab as a therapeutic option against COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.09.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strategy for treating the disease. Siltuximab is a monoclonal antibody indicated in Castleman's disease that could be administered in a single dose of 11 mg/kg in severe forms of COVID-19 that have increased interleukin 6 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a clinical pharmacy | |
| 650 | 4 | |a hospital pharmacy education | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a infectious diseases | |
| 650 | 4 | |a intensive & critical care | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a IL6 protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a siltuximab |2 NLM | |
| 650 | 7 | |a T4H8FMA7IM |2 NLM | |
| 700 | 1 | |a López-Briz, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Poveda Andrés, José Luis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of hospital pharmacy : science and practice |d 2012 |g 27(2020), 5 vom: 04. Sept., Seite 297-298 |w (DE-627)NLM225772213 |x 2047-9956 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2020 |g number:5 |g day:04 |g month:09 |g pages:297-298 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/ejhpharm-2020-002322 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2020 |e 5 |b 04 |c 09 |h 297-298 | ||